The White House and Pharma were *this close* to a deal to lower Medicare drug spending by $150 billion over 10 years. But it blew up because the White House wanted to mail discount cards to Medicare beneficiaries before the election. nytimes.com/2020/09/18/us/…@jmartNYT@maggieNYT
Pharma balked at "Trump cards," which is why the president, for the second time, signed an executive order that says it will lower Medicare drug prices to the lowest price paid by foreign countries. whitehouse.gov/presidential-a…
As you may remember, the president signed such an order in July, too. But the White House never published the order in the Federal Register, as required by law. nytimes.com/2020/08/24/us/…
That order finally became public on Sunday, along with the. new one. But the new one somehow rescinds the previously unpublished order. (Here it is: whitehouse.gov/presidential-a…)
It is true that the pharmaceutical industry loathes the approach taken by this order, which would establish price controls--with low prices--for drugs purchased for Medicare beneficiaries. But the order itself is a long way from actually affecting drug prices paid by anyone.
Part of the order, which seeks to influence the prices paid for Medicare Part D drugs, seems legally vulnerable. The legislation establishing the program specifically bars the federal government from negotiating directly with the manufacturers. nytimes.com/2019/07/05/ups…
Lawsuits seem inevitable.
But aside from legal challenges, these programs will need to be designed through notice and comment rulemaking, and as pilot programs before they will go Medicare-wide. Look at the careful language here for a preview of what regulators will face.
All of which is to say: Drug prices are not going down before the election.
But it appears that Pharma was willing to make a deal that would have handed both sides a win right away. nytimes.com/2020/09/18/us/…
One final thought. I know many of these budget numbers sound like monopoly money. But $150 billion is a huge number.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
If you want to understand the problem of "waste, fraud, and abuse" in federal health programs, you should read this great piece by @sarahkliff and @katie_thomas on scammy skin substitute comanies.
@sarahkliff @katie_thomas As they report, the companies that make these skin substitutes--a fancy kind of bandage--have exploited loopholes in Medicare's pricing policies to charge high prices. Then they offer financial incentives to doctors to overuse them on patients. nytimes.com/2025/04/10/hea…
@sarahkliff @katie_thomas The current administration is hunting for ways to save money on wasteful spending. Yet Mr. Trump has posted on social media in support of the companies.
The Harris campaign is out today with a paper warning about what would happen if Trump repeals Obamacare. kamalaharris.com/wp-content/upl…
Also, today, I published a story about what would happen to subsidies for about $20 million people if the next president and Congress simply do nothing. nytimes.com/2024/09/30/ups…
The subsidies have brought down the price of insurance substantially--making it free for many low income families, and offering financial help to higher earners who got no assistance from Obamacare initially. But they will expire after next year without action.
Medicare slowth: still going. One of the great (fortunate) mysteries of our time. @aliciaparlap @jshkatznytimes.com/interactive/20…
@aliciaparlap @jshkatz First of all, credit to @ddiamond for coining the term "slowth," to mean slow growth.
@aliciaparlap @jshkatz @ddiamond Medicare has been a budget buster for so long that a lot of smart people have found the program's recent trend of slow growth surprising.
When I was reporting on this story about the fiscal impacts of the GOP debt ceiling bill, I stumbled upon a provision that was getting very little attention but would be hugely consequential. nytimes.com/interactive/20…
The provision is called the REINS Act, and is designed to get Congress more engaged in the details of how laws they pass get implemented--by forcing Congress to vote every major regulation up or down. nytimes.com/2023/05/12/ups…
I started calling regulatory policy experts. Almost none of them knew this policy had just passed the House. nytimes.com/2023/05/12/ups…
Be sure to read @atmccann on the growing abortion pill underground, full of incredible details and never-before-collected data. nytimes.com/interactive/20…
This channel has provided 50,000 pill packs to women since the Dobbs decision.
For context, @clairecm and I wrote about data suggesting that the number of legal abortions during this period fell by around 32,000. nytimes.com/2023/04/12/ups…
A technical Medicare Advantage model change, buried deep in the annual rate notice, has unleashed a lobbying frenzy. nytimes.com/2023/03/22/hea…@ReedAbelson
There is tons of evidence that insurers in the program have been manipulating a program that pays them extra fees for enrolling customers with more illnesses. The change took away payments for some of diagnoses that are gamed the most.
@ReedAbelson and I wrote last year about how nearly every major player in Medicare Advantage is facing a federal fraud lawsuit for this type of behavior. nytimes.com/2022/10/08/ups…